Immuneering reports preclinical data supporting atebimetinib combinations in pancreatic cancer
IMRX•Immuneering reported preclinical findings supporting atebimetinib combinations with KRAS and PRMT5 inhibitors for pancreatic cancer. The results are scheduled for presentation Nov. 19 at the EORTC-NCI-AACR Symposium.



